RET and non-small cell lung carcinoma: ,4 From the ARROW phase 1/2 trial in 281 patients with RET fusion-positive NSCLC, pralsetinib was found to have an objective response rate (ORR) of 59% (95% confidence interval [CI]: 50%–67%) and a median progression-free survival (PFS) of 16.5 months (95% CI: 10.5–24.1) in pretreated patients.5